Hepatitis C and injecting drug use: impact, costs and policy options
Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph. A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication pres...
| Contributors: | |
|---|---|
| Format: | Electronic Book |
| Language: | English |
| Published: |
Luxemburg
Office for Official Publications of the European Communities
2004
|
| In: |
EMCDDA scientific monograph series (7)
|
| Online Access: |
Volltext (kostenfrei) Volltext (kostenfrei) Volltext (kostenfrei) |
| Check availability: | HBZ Gateway |
| Keywords: | |
| Related Items: | Erscheint auch als:
471720607 |
| Summary: | Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph. A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication presents analyses on the impact and costs of the disease among injecting drug users, as a basis for sound policy-making. Other issues addressed include: quality of life; treatment, surveillance and prevention; and the cost-effectiveness of measures such as needle-exchange programmes and substitution therapy. Hepatitis C affects an estimated 170 million people worldwide and at least a million, but possibly several million, people in Western Europe who are at risk of developing liver cirrhosis or liver cancer. It is a highly infectious and potentially fatal blood-borne disease that attacks the liver and for which there is as yet no vaccine. |
|---|---|
| Physical Description: | 1 Online-Ressource (391 Seiten) |
| DOI: | 10.15496/publikation-23211 |